These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

326 related items for PubMed ID: 39325101

  • 21. Quantitative insight into the design of compounds recognized by the L-type amino acid transporter 1 (LAT1).
    Ylikangas H, Malmioja K, Peura L, Gynther M, Nwachukwu EO, Leppänen J, Laine K, Rautio J, Lahtela-Kakkonen M, Huttunen KM, Poso A.
    ChemMedChem; 2014 Dec; 9(12):2699-707. PubMed ID: 25205473
    [Abstract] [Full Text] [Related]

  • 22. Design, synthesis and brain uptake of LAT1-targeted amino acid prodrugs of dopamine.
    Peura L, Malmioja K, Huttunen K, Leppänen J, Hämäläinen M, Forsberg MM, Gynther M, Rautio J, Laine K.
    Pharm Res; 2013 Oct; 30(10):2523-37. PubMed ID: 24137801
    [Abstract] [Full Text] [Related]

  • 23. Large Amino Acid Transporter 1 Selective Liposomes of l-DOPA Functionalized Amphiphile for Combating Glioblastoma.
    Bhunia S, Vangala V, Bhattacharya D, Ravuri HG, Kuncha M, Chakravarty S, Sistla R, Chaudhuri A.
    Mol Pharm; 2017 Nov 06; 14(11):3834-3847. PubMed ID: 28958145
    [Abstract] [Full Text] [Related]

  • 24. Reevaluating the Substrate Specificity of the L-Type Amino Acid Transporter (LAT1).
    Chien HC, Colas C, Finke K, Springer S, Stoner L, Zur AA, Venteicher B, Campbell J, Hall C, Flint A, Augustyn E, Hernandez C, Heeren N, Hansen L, Anthony A, Bauer J, Fotiadis D, Schlessinger A, Giacomini KM, Thomas AA.
    J Med Chem; 2018 Aug 23; 61(16):7358-7373. PubMed ID: 30048132
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. The human LAT1-4F2hc (SLC7A5-SLC3A2) transporter complex: Physiological and pathophysiological implications.
    Kahlhofer J, Teis D.
    Basic Clin Pharmacol Toxicol; 2023 Nov 23; 133(5):459-472. PubMed ID: 36460306
    [Abstract] [Full Text] [Related]

  • 28. Structure-activity relationship study of compounds binding to large amino acid transporter 1 (LAT1) based on pharmacophore modeling and in situ rat brain perfusion.
    Ylikangas H, Peura L, Malmioja K, Leppänen J, Laine K, Poso A, Lahtela-Kakkonen M, Rautio J.
    Eur J Pharm Sci; 2013 Feb 14; 48(3):523-31. PubMed ID: 23228412
    [Abstract] [Full Text] [Related]

  • 29. The L-type amino acid transporter 1 enhances drug delivery to the mouse pancreatic beta cell line (MIN6).
    Tampio J, Montaser AB, Järvinen J, Lehtonen M, Jalkanen AJ, Reinisalo M, Kokkola T, Terasaki T, Laakso M, Rysä J, Kauppinen A, Huttunen KM.
    Eur J Pharm Sci; 2024 Dec 01; 203():106937. PubMed ID: 39419128
    [Abstract] [Full Text] [Related]

  • 30. Amino acid transporter LAT1 (SLC7A5) as a molecular target for cancer diagnosis and therapeutics.
    Kanai Y.
    Pharmacol Ther; 2022 Feb 01; 230():107964. PubMed ID: 34390745
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Insights into the Structure, Function, and Ligand Discovery of the Large Neutral Amino Acid Transporter 1, LAT1.
    Singh N, Ecker GF.
    Int J Mol Sci; 2018 Apr 24; 19(5):. PubMed ID: 29695141
    [Abstract] [Full Text] [Related]

  • 33. Alzheimer's Disease Phenotype or Inflammatory Insult Does Not Alter Function of L-Type Amino Acid Transporter 1 in Mouse Blood-Brain Barrier and Primary Astrocytes.
    Gynther M, Puris E, Peltokangas S, Auriola S, Kanninen KM, Koistinaho J, Huttunen KM, Ruponen M, Vellonen KS.
    Pharm Res; 2018 Nov 28; 36(1):17. PubMed ID: 30488131
    [Abstract] [Full Text] [Related]

  • 34. Site-directed mutagenesis of cysteine residues of large neutral amino acid transporter LAT1.
    Boado RJ, Li JY, Chu C, Ogoshi F, Wise P, Pardridge WM.
    Biochim Biophys Acta; 2005 Sep 15; 1715(2):104-10. PubMed ID: 16125134
    [Abstract] [Full Text] [Related]

  • 35. Cryo-EM structure of the human L-type amino acid transporter 1 in complex with glycoprotein CD98hc.
    Lee Y, Wiriyasermkul P, Jin C, Quan L, Ohgaki R, Okuda S, Kusakizako T, Nishizawa T, Oda K, Ishitani R, Yokoyama T, Nakane T, Shirouzu M, Endou H, Nagamori S, Kanai Y, Nureki O.
    Nat Struct Mol Biol; 2019 Jun 15; 26(6):510-517. PubMed ID: 31160781
    [Abstract] [Full Text] [Related]

  • 36. Role of l-Type Amino Acid Transporter 1 at the Inner Blood-Retinal Barrier in the Blood-to-Retina Transport of Gabapentin.
    Akanuma SI, Yamakoshi A, Sugouchi T, Kubo Y, Hartz AMS, Bauer B, Hosoya KI.
    Mol Pharm; 2018 Jun 04; 15(6):2327-2337. PubMed ID: 29688723
    [Abstract] [Full Text] [Related]

  • 37. Structure of the human LAT1-4F2hc heteromeric amino acid transporter complex.
    Yan R, Zhao X, Lei J, Zhou Q.
    Nature; 2019 Apr 04; 568(7750):127-130. PubMed ID: 30867591
    [Abstract] [Full Text] [Related]

  • 38. Amino Acid Promoieties Alter Valproic Acid Pharmacokinetics and Enable Extended Brain Exposure.
    Gynther M, Peura L, Vernerová M, Leppänen J, Kärkkäinen J, Lehtonen M, Rautio J, Huttunen KM.
    Neurochem Res; 2016 Oct 04; 41(10):2797-2809. PubMed ID: 27412117
    [Abstract] [Full Text] [Related]

  • 39. Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug.
    Thiele NA, Kärkkäinen J, Sloan KB, Rautio J, Huttunen KM.
    Bioorg Med Chem Lett; 2018 Sep 15; 28(17):2856-2860. PubMed ID: 30055889
    [Abstract] [Full Text] [Related]

  • 40. Structural Features Affecting the Interactions and Transportability of LAT1-Targeted Phenylalanine Drug Conjugates.
    Bahrami K, Järvinen J, Laitinen T, Reinisalo M, Honkakoski P, Poso A, Huttunen KM, Rautio J.
    Mol Pharm; 2023 Jan 02; 20(1):206-218. PubMed ID: 36394563
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 17.